Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Cancer Lett. 2012 Jan 28;314(2):206-12. doi: 10.1016/j.canlet.2011.09.032. Epub 2011 Oct 1.
Association of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki67 and 70-gene classifier (70-GC) with a response to paclitaxel (PAC) (n=79) or docetaxel (DOC) (n=55) was investigated in the neoadjuvant setting for breast cancer patients. Sensitivity of breast tumors to PAC, but not to DOC, was found to be significantly associated with ER negativity (P=0.003), PR negativity (P=0.007), and Ki67 positivity (P=0.007). Breast tumors classified into the responders by 70-GC showed a significantly (P=0.005) higher reduction rate to PAC and interestingly a significantly (P=0.009) lower reduction rate to DOC than those classified into the non-responders by 70-GC, suggesting that 70-GC might be useful for the differentiation of PAC-sensitive and DOC-sensitive breast tumors.
在乳腺癌新辅助治疗中，研究了雌激素受体 (ER)、孕激素受体 (PR)、HER2、Ki67 和 70 基因分类器 (70-GC) 与紫杉醇 (PAC) (n=79) 或多西紫杉醇 (DOC) (n=55) 反应之间的关系。发现乳腺肿瘤对 PAC 的敏感性，而不是对 DOC 的敏感性，与 ER 阴性 (P=0.003)、PR 阴性 (P=0.007) 和 Ki67 阳性 (P=0.007) 显著相关。通过 70-GC 分类为应答者的乳腺肿瘤对 PAC 的降低率显著升高 (P=0.005)，而有趣的是，与 70-GC 分类为非应答者的乳腺肿瘤相比，对 DOC 的降低率显著降低 (P=0.009)，这表明 70-GC 可能有助于区分 PAC 敏感和 DOC 敏感的乳腺肿瘤。
